Journal of the Formosan Medical Association
Volume 108, Issue 11 , Pages 827-829, November 2009

HIV-1 Vaccine—Many Miles to Go Before We Sleep

  • Kuan-Teh Jeang

      Affiliations

    • National Institutes of Health, Bethesda, Maryland, USA
    • Corresponding Author InformationCorrespondence to: Dr Kuan-Teh Jeang, Molecular Virology Section, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health Building 4, Room 306, 9000 Rockville Pike, Bethesda, Maryland 20892-0460, USA
    • ,
  • Li-Min Huang

      Affiliations

    • Department of Pediatrics, National Taiwan University, Taipei, Taiwan

Article Outline

No abstract is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Huang LM , Jeang KT . HIV-1 at age 25: some thoughts for Taiwan and China . J Formos Med Assoc . 2008;107:907–908
  2. Shao Y . AIDS epidemic at age 25 and control efforts in China . Retrovirology . 2006;3:87
  3. Chen J , Hong K , Jia M , et al.   Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B′/C Recombinant (CRF07_BC) . Retrovirology . 2007;4:62
  4. Wainberg MA , Jeang KT . 25 years of HIV-1 research— progress and perspectives . BMC Med . 2008;6:31
  5. Flynn NM , Forthal DN , Harro CD , et al.   Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection . J Infect Dis . 2005;191:654–665
  6. Buchbinder SP , Mehrotra DV , Duerr A , et al.   Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial . Lancet . 2008;372:1881–1893
  7. Pitisuttithum P , Gilbert P , Gurwith M , et al.   Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand . J Infect Dis . 2006;194:1661–1671
  8. Iaccino E , Schiavone M , Fiume G , et al.   The aftermath of the Merck's HIV vaccine trial . Retrovirology . 2008;5:56
  9. Rerks-Ngarm S , Pitisuttithum P , Nitayaphan S , et al.   Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand . N Engl J Med . 2009 Oct 20; [Epub ahead of print]
  10. Brittain E , Lin D . A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials . Stat Med . 2005;24:1–10
  11. Wright CC , Sim J . Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis . J Clin Epidemiol . 2003;56:833–842
  12. Sheiner LB , Rubin DB . Intention-to-treat analysis and the goals of clinical trials . Clin Pharmacol Ther . 1995;7:6–15
  13. Heritier SR , Gebski VJ , Keech AC . Inclusion of patients in clinical trial analysis: the intention-to-treat principle . Med J Aust . 2003;179:438–440
  14. Porta N , Bonet C , Cobo E . Discordance between reported intention-to-treat and per protocol analyses . J Clin Epidemiol . 2007;60:663–669
  15. Berkhout B , Paxton WA . HIV vaccine: it may take two to tango, but no party time yet . Retrovirology . 2009;6:88
  16. Lama J , Planelles V . Host factors influencing susceptibility to HIV infection and AIDS progression . Retrovirology . 2007;4:52
  17. Strebel K , Luban J , Jeang KT . Human cellular restriction factors that target HIV-1 replication . BMC Med . 2009;7:48

PII: S0929-6646(09)60412-5

doi:10.1016/S0929-6646(09)60412-5

Journal of the Formosan Medical Association
Volume 108, Issue 11 , Pages 827-829, November 2009

Article Tools